Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) Meeting Abstract
| Authors: | Tsurutani, J.; Jacot, W.; Yamashita, T.; Riaz, F.; Yerushalmi, R.; Im, S. A.; Niikura, N.; Halser-Strub, U.; CorteĢs, J.; Wennstig, A. K.; Chae, Y.; Wang, X.; Li, W.; Simon, H.; Masci, G.; Tamburini, E.; Aguilar, C. O.; Tecson, K.; Yung, L.; Modi, S. |
| Abstract Title: | Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S342 |
| End Page: | S343 |
| Language: | English |
| ACCESSION: | WOS:001087480200377 |
| DOI: | 10.1016/j.annonc.2023.09.565 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 388P -- Source: Wos |
